Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy

Samankaltaisia teoksia

• Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines
  Tekijä: Khushman, Moh’d, et al.
  Julkaistu: (2018)
• The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens
  Tekijä: Khushman, Moh’d, et al.
  Julkaistu: (2021)
• The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population
  Tekijä: Abbasian, Mohammad Hadi, et al.
  Julkaistu: (2020)
• Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
  Tekijä: Wigle, Theodore J., et al.
  Julkaistu: (2021)
• Pancreatic Cancer Exosomes: Shedding Off for a Meaningful Journey
  Tekijä: Patel, Girijesh Kumar, et al.
  Julkaistu: (2016)